[1]
|
Bahrami, A.A., Payandeh, Z., Khalili, S., et al. (2019) Immunoinformatics: In Silico Approaches and Computational De-sign of a Multi-Epitope, Immunogenic Protein. International Reviews of Immunology, 38, 307-322.
https://doi.org/10.1080/08830185.2019.1657426
|
[2]
|
Doneva, N., Doytchinova, I. and Dimitrov, I. (2021) Pre-dicting Immunogenicity Risk in Biopharmaceuticals. Symmetry-Basel, 13, Article No. 388. https://doi.org/10.3390/sym13030388
|
[3]
|
Faraji, F., Karjoo, Z., Moghaddam, M.V., et al. (2018) Challenges Re-lated to the Immunogenicity of Parenteral Recombinant Proteins: Underlying Mechanisms and New Approaches to Overcome It. International Reviews of Immunology, 37, 301-315. https://doi.org/10.1080/08830185.2018.1471139
|
[4]
|
Treanor, B. (2012) B-Cell Receptor: From Resting State to Activate. Immunology, 136, 21-27.
https://doi.org/10.1111/j.1365-2567.2012.03564.x
|
[5]
|
Saha, S. and Raghava, G.P.S. (2004) BcePred: Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-Chemical Properties. In: Nicosia, G., Cutello, V., Bentley, P.J., et al., Eds., Artificial Immune Systems, Proceedings, Springer, Berlin, 197-204. https://doi.org/10.1007/978-3-540-30220-9_16
|
[6]
|
Saha, S. and Raghava, G.P.S. (2006) Prediction of Continuous B-Cell Epitopes in an Antigen Using Recurrent Neural Network. Proteins-Structure Function and Bioinformatics, 65, 40-48. https://doi.org/10.1002/prot.21078
|
[7]
|
Andersen, P.H., Nielsen, M. and Lund, O. (2006) Prediction of Residues in Discontinuous B-Cell Epitopes Using Protein 3D Structures. Protein Science, 15, 2558-2567. https://doi.org/10.1110/ps.062405906
|
[8]
|
Ponomarenko, J., Bui, H.H., Li, W., et al. (2008) ElliPro: A New Structure-Based Tool for the Prediction of Antibody Epitopes. BMC Bioinformatics, 9, Article No. 514. https://doi.org/10.1186/1471-2105-9-514
|
[9]
|
Reche, P.A., Glutting, J.P. and Reinherz, E.L. (2002) Prediction of MHC Class I Binding Peptides Using Profile Motifs. Human Immunology, 63, 701-709. https://doi.org/10.1016/S0198-8859(02)00432-9
|
[10]
|
Oyarzún, P., Ellis, J.J., Bodén, M., et al. (2013) PREDIVAC: CD4+ T-Cell Epitope Prediction for Vaccine Design That Covers 95% of HLA Class II DR Protein Diversity. BMC Bi-oinformatics, 14, Article No. 52.
https://doi.org/10.1186/1471-2105-14-52
|
[11]
|
Perez-Ruiz, F., Calabozo, M., Erauskin, G.G., et al. (2002) Renal Underexcretion of Uric Acid Is Present in Patients with Apparent High Urinary Uric Acid Output. Arthritis and Rheu-matism, 47, 610-613.
https://doi.org/10.1002/art.10792
|
[12]
|
Maiuolo, J., Oppedisano, F., Gratteri, S., et al. (2016) Regulation of Uric Acid Metabolism and Excretion. International Journal of Cardiology, 213, 8-14. https://doi.org/10.1016/j.ijcard.2015.08.109
|
[13]
|
Cortes, J., Moore, J.O., Maziarz, R.T., et al. (2010) Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasbu-ricase Followed by Allopurinol Compared with Allopurinol Alone-Results of a Multicenter Phase III Study. Journal of Clinical Oncology, 28, 4207-4213.
https://doi.org/10.1200/JCO.2009.26.8896
|
[14]
|
Navolanic, P.M., Pui, C.H., Larson, R.A., et al. (2003) Elitek (TM)-Rasburicase: An Effective Means to Prevent and Treat Hyperuricemia Associated with Tumor Lysis Syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 17, 499-514. https://doi.org/10.1038/sj.leu.2402847
|
[15]
|
Shannon, J.A. and Cole, S.W. (2012) Pegloticase: A Novel Agent for Treatment-Refractory Gout. Annals of Pharmacotherapy, 46, 368-76. https://doi.org/10.1345/aph.1Q593
|
[16]
|
Lipsky, P.E., Calabrese, L.H., Kavanaugh, A., et al. (2014) Pegloticase Immunogenicity: The Relationship between Efficacy and Antibody Development in Patients Treated for Refractory Chronic Gout. Arthritis Research & Therapy, 16, R60. https://doi.org/10.1186/ar4497
|
[17]
|
Nelapati, A.K., Das, B.K., Ettiyappan, J.B.P., et al. (2020) In-Silico Epitope Identification and Design of Uricase Mutein with Reduced Im-munogenicity. Process Biochemistry, 92, 288-302.
https://doi.org/10.1016/j.procbio.2020.01.022
|
[18]
|
Tripathi, S., Parmar, J. and Kumar, A. (2020) Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach. Protein Journal, 39, 133-144. https://doi.org/10.1007/s10930-020-09886-0
|
[19]
|
Labrou, N.E., Papageorgiou, A.C. and Avramis, V.I. (2010) Structure-Function Relationships and Clinical Applications of L-Asparaginases. Current Medicinal Chemistry, 17, 2183-2195. https://doi.org/10.2174/092986710791299920
|
[20]
|
Yen, H.J., Chang, W.H., Liu, H.C., et al. (2016) Outcomes Following Discontinuation of E. coli L-Asparaginase upon Severe Allergic Reactions in Children with Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer, 63, 665-670.
https://doi.org/10.1002/pbc.25869
|
[21]
|
Ramya, L.N. and Pulicherla, K.K. (2015) Studies on Deimmunization of Antileukaemic L-Asparaginase to Have Reduced Clinical Immunogenicity—An in Silico Approach. Pathology and On-cology Research, 21, 909-920.
https://doi.org/10.1007/s12253-015-9912-0
|
[22]
|
Mohd Asri, N.A., Ahmad, S., Mohamud, R., et al. (2021) Global Prevalence of Nosocomial Multidrug-Resistant Klebsiella pneumoniae: A Systematic Review and Meta-Analysis. Antibi-otics (Basel, Switzerland), 10, Article No. 1508.
https://doi.org/10.3390/antibiotics10121508
|
[23]
|
Rostamian, M., Farasat, A., Lorestani, R.C., et al. (2022) Im-munoinformatics and Molecular Dynamics Studies to Predict T-Cell-Specific Epitopes of Four Klebsiella pneumonia Fimbriae Antigens. Journal of Biomolecular Structure & Dynamics, 40, 166-176. https://doi.org/10.1080/07391102.2020.1810126
|
[24]
|
Neefjes, J., Jongsma, M.L.M., Paul, P., et al. (2011) To-wards a Systems Understanding of MHC Class I and MHC Class II Antigen Presentation. Nature Reviews Immunology, 11, 823-836. https://doi.org/10.1038/nri3084
|